Literature DB >> 1626557

Hepatotoxicity associated with sustained-release niacin.

T A Dalton1, R S Berry.   

Abstract

Niacin (nicotinic acid) is a widely used agent in the treatment of hyperlipidemias characterized by elevated low-density lipoprotein and very-low-density lipoprotein. The tendency of the conventional crystalline niacin to cause flushing has limited its use in many patients. Sustained-release (SR) niacin preparations are increasingly utilized due to a lower incidence of flushing and convenient dosing frequency. Although gastrointestinal and hepatotoxic side effects are common to both formulations, they are more frequent and occasionally more severe with the SR preparations. We describe a patient who developed an acute illness characterized by hypothermia, hypotension, metabolic acidosis, and severe hepatic dysfunction 2 days after substitution of an SR preparation for a previously well-tolerated crystalline niacin.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1626557     DOI: 10.1016/0002-9343(92)90689-9

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  14 in total

Review 1.  Vitamin supplementation therapy in the elderly.

Authors:  J E Thurman; A D Mooradian
Journal:  Drugs Aging       Date:  1997-12       Impact factor: 3.923

2.  Excess vitamin intake: An unrecognized risk factor for obesity.

Authors:  Shi-Sheng Zhou; Yiming Zhou
Journal:  World J Diabetes       Date:  2014-02-15

Review 3.  Niacin: another look at an underutilized lipid-lowering medication.

Authors:  Julia C Creider; Robert A Hegele; Tisha R Joy
Journal:  Nat Rev Endocrinol       Date:  2012-02-21       Impact factor: 43.330

4.  Discovery of a potent nicotinic Acid receptor agonist for the treatment of dyslipidemia.

Authors:  Jun Qin; Ashwin Rao; Xiao Chen; Xiaohong Zhu; Zhidan Liu; Xianhai Huang; Sylvia Degrado; Ying Huang; Dong Xiao; Robert Aslanian; Boonlert Cheewatrakoolpong; Hongtao Zhang; Scott Greenfeder; Constance Farley; John Cook; Stan Kurowski; Qiu Li; Margaret van Heek; Madhu Chintala; Ganfeng Wang; Yunsheng Hsieh; Fangbiao Li; Anandan Palani
Journal:  ACS Med Chem Lett       Date:  2010-12-08       Impact factor: 4.345

5.  Safety and efficacy of extended-release niacin for the treatment of dyslipidaemia in patients with HIV infection: AIDS Clinical Trials Group Study A5148.

Authors:  Michael P Dubé; Julia W Wu; Judith A Aberg; Mark A Deeg; Beverly L Alston-Smith; Mark E McGovern; Daniel Lee; Sharon L Shriver; Ana I Martinez; Martha Greenwald; James H Stein
Journal:  Antivir Ther       Date:  2006

Review 6.  Nicotinic acid: an old drug with a promising future.

Authors:  E T Bodor; S Offermanns
Journal:  Br J Pharmacol       Date:  2007-11-26       Impact factor: 8.739

Review 7.  Lipid-lowering agents that cause drug-induced hepatotoxicity.

Authors:  Sidharth S Bhardwaj; Naga Chalasani
Journal:  Clin Liver Dis       Date:  2007-08       Impact factor: 6.126

Review 8.  Niacin, an old drug with a new twist.

Authors:  Wen-Liang Song; Garret A FitzGerald
Journal:  J Lipid Res       Date:  2013-08-15       Impact factor: 5.922

Review 9.  Biological Properties of Vitamins of the B-Complex, Part 1: Vitamins B1, B2, B3, and B5.

Authors:  Marcel Hrubša; Tomáš Siatka; Iveta Nejmanová; Marie Vopršalová; Lenka Kujovská Krčmová; Kateřina Matoušová; Lenka Javorská; Kateřina Macáková; Laura Mercolini; Fernando Remião; Marek Máťuš; Přemysl Mladěnka
Journal:  Nutrients       Date:  2022-01-22       Impact factor: 5.717

Review 10.  Prolonged-release nicotinic acid for the management of dyslipidemia: an update including results from the NAUTILUS study.

Authors:  Anja Vogt; Ursula Kassner; Ulrike Hostalek; Elisabeth Steinhagen-Thiessen
Journal:  Vasc Health Risk Manag       Date:  2007
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.